Horizon Therapeutics Public - HZNP Stock Forecast, Price & News

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HZNP shares.
View HZNP analyst ratings or view top-rated stocks.

8 equities research analysts have issued 1 year target prices for Horizon Therapeutics Public's shares. Their HZNP share price forecasts range from $71.00 to $144.00. On average, they expect the company's stock price to reach $117.22 in the next twelve months. This suggests a possible upside of 89.4% from the stock's current price.
View analysts price targets for HZNP or view top-rated stocks among Wall Street analysts.

Horizon Therapeutics Public's stock was trading at $107.76 at the beginning of the year. Since then, HZNP stock has decreased by 42.6% and is now trading at $61.89.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our HZNP earnings forecast.

Horizon Therapeutics Public Limited (NASDAQ:HZNP) announced its quarterly earnings data on Wednesday, August, 3rd. The biopharmaceutical company reported $1.07 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.36 by $0.29. The biopharmaceutical company had revenue of $876.40 million for the quarter, compared to the consensus estimate of $938.82 million. Horizon Therapeutics Public had a net margin of 20.06% and a trailing twelve-month return on equity of 27.90%. The company's revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.62 earnings per share.

Horizon Therapeutics Public issued an update on its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $3.53 billion-$3.60 billion, compared to the consensus revenue estimate of $3.96 billion.

70 employees have rated Horizon Therapeutics Public Chief Executive Officer Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL).

Horizon Therapeutics Public trades on the NASDAQ under the ticker symbol "HZNP."

Shares of HZNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HZNP stock can currently be purchased for approximately $61.89.

Horizon Therapeutics Public (NASDAQ:HZNP) has a market capitalization of $14.26 billion and generates $3.23 billion in revenue each year. The biopharmaceutical company earns $534.49 million in net income (profit) each year or $3.24 on an earnings per share basis.

The company employs 1,890 workers across the globe.

Horizon Therapeutics Public's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The official website for the company is www.horizontherapeutics.com. The biopharmaceutical company can be reached via phone at (531) 772-2100, via email at investor-relations@horizontherapeutics.com, or via fax at 224-383-3001.